


## (±)-Fabesetron hydrochloride

### Chemical Properties

CAS No. : 129299-81-6  
 Formula: C<sub>18</sub>H<sub>20</sub>ClN<sub>3</sub>O  
 Molecular Weight: 329.82  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
*Actual storage temperature shall be subject to the COA.*



### Biological Description

Description	FK1052 hydrochloride is a potent 5-HT <sub>3</sub> and 5-HT <sub>4</sub> receptor dual antagonist.
Targets(IC <sub>50</sub> )	5-HT Receptor
In vivo	FK1052 (1 mg/kg i.v. ×4) apparently reduces delayed emesis caused by Methotrexate (MTX) and increases, but not significantly, the time for onset of emesis. Furthermore, increasing the dose to 3.2 mg/kg of FK1052 also significantly inhibits the number of the emetic episodes induced by MTX, of which the action is more effective than the treatment with FK1052 at 1 mg/kg. In conscious rats, both 5-HT and 5-methoxytryptamine significantly increase fecal pellet output and accelerate colonic transit. In contrast, the effect of 2-methyl-5-HT is slight. Although Ondansetron and Granisetron slightly reduce 5-HT (1 mg/kg s.c.) stimulated colonic transit, FK1052, at 0.1 mg/kg p.o., inhibits completely the increases in the colonic transit. Furthermore, FK1052, Ondansetron and Granisetron significantly depress the increase in fecal pellet output caused by wrap-restraint stress, with ED <sub>50</sub> values of 0.21, 3.0 and 1.1 mg/kg p.o., respectively. Intraperitoneal administration of 5-HT and 5-methoxytryptamine, but not 2-methyl-5-HT, produces a dose-related increase in the incidence of diarrhea in fasted mice. 5-HT (0.32 mg/kg i.p.)-induced diarrhea is also inhibited by FK1052, Ondansetron and Granisetron, with ED <sub>50</sub> values of 0.09, 2.3 and 0.88 mg/kg p.o., respectively.

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	3.032 mL	15.1598 mL	30.3196 mL
5 mM	0.6064 mL	3.032 mL	6.0639 mL
10 mM	0.3032 mL	1.516 mL	3.032 mL
50 mM	0.0606 mL	0.3032 mL	0.6064 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Kadowaki M, et al. Effect of FK1052, a potent 5-hydroxytryptamine<sub>3</sub> and 5-hydroxytryptamine<sub>4</sub> receptor dual antagonist, on colonic function in vivo. *J Pharmacol Exp Ther.* 1993 Jul;266(1):74-80.

Yamakuni H, et al. Probable involvement of the 5-hydroxytryptamine(4) receptor in methotrexate-induced delayed emesis in dogs. *J Pharmacol Exp Ther.* 2000 Mar;292(3):1002-7.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481